Literature DB >> 17082898

Clinically non-functioning pituitary adenoma.

Craig A Jaffe1.   

Abstract

Non-functioning pituitary tumors are relatively common. A large number of these tumors are incidentally found pituitary microadenomas (<1 cm) and are usually of no clinical importance. Those tumors that require treatment are generally macroadenomas and come to medical attention because of mass effect and/or hypopituitarism. Visual field defects are present in roughly 70% of patients with non-functioning macroadenoma at the time of diagnosis and the majority of these patients have at least growth deficiency and hypogonadism. By immunocytochemistry, the large majority of these tumors are glycoprotein producing and less commonly they are non-functioning somatotroph, lactotroph or corticotoph adenomas. In contrast to the immunocytochemistry results, only a minority of these tumors actively secrete intact gonadotrophs or glycoprotein subunits. Therapy is directed at eliminating mass effect and correcting hypopituitarism. There are anecdotal reports of tumor shrinkage during therapy with either dopamine agonists or somatostatin agonists; however tumor response to medical treatment is not reliable. For most patients, transphenoidal resection of the tumor is the preferable primary treatment. Surgery improves visual defects in the majority of patients and a lesser number will recover pituitary function. In the past, pituitary radiation was commonly administered following pituitary surgery; however the need for routine radiation has recently been reevaluated. Although tumor recurrence at 10 years post surgery may be as high as 50%, few patients with recurrence will have clinical symptoms. Close follow-up with surveillance pituitary scans should be performed after surgery and radiation therapy reserved for patients having significant tumor recurrence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082898     DOI: 10.1007/s11102-006-0412-9

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  16 in total

1.  Biochemical markers for clinically non-functioning pituitary tumours.

Authors:  P E Harris
Journal:  Clin Endocrinol (Oxf)       Date:  1998-08       Impact factor: 3.478

Review 2.  Pituitary incidentalomas.

Authors:  D C Aron; T A Howlett
Journal:  Endocrinol Metab Clin North Am       Date:  2000-03       Impact factor: 4.741

Review 3.  Medical therapy for gonadotroph and thyrotroph tumors.

Authors:  M E Shomali; L Katznelson
Journal:  Endocrinol Metab Clin North Am       Date:  1999-03       Impact factor: 4.741

4.  Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas.

Authors:  K O Lillehei; D L Kirschman; B K Kleinschmidt-DeMasters; E C Ridgway
Journal:  Neurosurgery       Date:  1998-09       Impact factor: 4.654

5.  Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas.

Authors:  S M Webb; M Rigla; A Wägner; B Oliver; F Bartumeus
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

6.  Dopamine agonists and pituitary tumor shrinkage.

Authors:  J S Bevan; J Webster; C W Burke; M F Scanlon
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

7.  Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.

Authors:  T Lohmann; C Trantakis; M Biesold; S Prothmann; S Guenzel; R Schober; R Paschke
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

8.  Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth.

Authors:  Y Greenman; G Ouaknine; I Veshchev; I I Reider-Groswasser; Y Segev; N Stern
Journal:  Clin Endocrinol (Oxf)       Date:  2003-06       Impact factor: 3.478

9.  Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas.

Authors:  A Colao; G Cerbone; P Cappabianca; D Ferone; A Alfieri; F Di Salle; A Faggiano; B Merola; E de Divitiis; G Lombardi
Journal:  J Endocrinol Invest       Date:  1998-05       Impact factor: 4.256

10.  The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas.

Authors:  Paul Park; William F Chandler; Ariel L Barkan; John J Orrego; John A Cowan; Kent A Griffith; Christina Tsien
Journal:  Neurosurgery       Date:  2004-07       Impact factor: 4.654

View more
  28 in total

Review 1.  Potential role of type I interferons in the treatment of pituitary adenomas.

Authors:  Giovanni Vitale; Michele Caraglia; Peter M van Koetsveld; Paola Maroni; Monica Marra; Annamaria Colao; Steven W J Lamberts; Francesco Cavagnini; Leo J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-06       Impact factor: 6.514

2.  Outcome of pituitary hormone deficits after surgical treatment of nonfunctioning pituitary macroadenomas.

Authors:  Orsalia Alexopoulou; Valérie Everard; Martine Etoa; Edward Fomekong; Stéphane Gaillard; Fabrice Parker; Christian Raftopoulos; Philippe Chanson; Dominique Maiter
Journal:  Endocrine       Date:  2021-04-14       Impact factor: 3.633

3.  Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas.

Authors:  Erica C Garcia; Luciana A Naves; Arthur O Silva; Lucas F de Castro; Luiz A Casulari; Monalisa F Azevedo
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

4.  Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study.

Authors:  Alessandra Fusco; Antonella Giampietro; Antonio Bianchi; Vincenzo Cimino; Francesca Lugli; Serena Piacentini; Margherita Lorusso; Anna Tofani; Germano Perotti; Libero Lauriola; Carmelo Anile; Giulio Maira; Alfredo Pontecorvi; Laura De Marinis
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

Review 5.  Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach.

Authors:  Xun Zhang; Yunli Zhou; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2010-03-06       Impact factor: 4.102

6.  Complete evaluation of pituitary tumours in a single tertiary care institution.

Authors:  Dimitrios Askitis; Damianos Tsitlakidis; Nicolle Müller; Albrecht Waschke; Gunter Wolf; Ulrich Alfons Müller; Christof Kloos
Journal:  Endocrine       Date:  2018-03-12       Impact factor: 3.633

7.  Non-invasive radiomics approach potentially predicts non-functioning pituitary adenomas subtypes before surgery.

Authors:  Shuaitong Zhang; Guidong Song; Yali Zang; Jian Jia; Chao Wang; Chuzhong Li; Jie Tian; Di Dong; Yazhuo Zhang
Journal:  Eur Radiol       Date:  2018-03-23       Impact factor: 5.315

8.  Spontaneous Pituitary Adenomas in Squirrel Monkeys (Saimiri sciureus).

Authors:  Gregory J Daggett; Jennifer S Wood; Sanjeev Gumber; Christopher J Pinelli
Journal:  Comp Med       Date:  2019-11-20       Impact factor: 0.982

9.  Differential expression of the Notch1 receptor, and its ligands Dll1, Dll3 and Dll4 in distinct human pituitary adenoma subtypes.

Authors:  Jianfu Zhang; Hua Gao; Yazhuo Zhang
Journal:  Oncol Lett       Date:  2017-04-05       Impact factor: 2.967

Review 10.  Genomics and genetics of gonadotropin beta-subunit genes: Unique FSHB and duplicated LHB/CGB loci.

Authors:  Liina Nagirnaja; Kristiina Rull; Liis Uusküla; Pille Hallast; Marina Grigorova; Maris Laan
Journal:  Mol Cell Endocrinol       Date:  2010-05-19       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.